Early and Midterm Outcomes of INSPIRIS RESILIA Versus AVALUS: A Propensity Score Matching Analysis

Area of Science:

• Cardiovascular Surgery
• Bioprosthetic Heart Valves
• Aortic Valve Replacement

Background:

• Aortic valve replacement (AVR) is a critical procedure for managing aortic valve disease.
• Bioprosthetic valves are commonly used, with ongoing development of new technologies.
• Comparing the clinical performance of different bioprosthetic valves is essential for surgical decision-making.

Purpose of the Study:

• To compare the early and midterm clinical outcomes of AVR using the INSPIRIS RESILIA bioprosthesis (IR-B) versus the AVALUS bioprosthesis (AV-B).

Main Methods:

• A single-centre retrospective study of 256 patients undergoing AVR between August 2018 and June 2023.
• Patients received either the INSPIRIS RESILIA bioprosthesis (n=156) or the AVALUS bioprosthesis (n=100).
• Propensity score matching was used to compare freedom from death, freedom from major adverse cardiovascular events (MACE), and echocardiographic data.

Main Results:

• After propensity score matching, 1-year survival rates were 93.8% (IR-B) and 94.5% (AV-B), with no significant difference at 3 years (p=0.88).
• Freedom from MACE at 3 years was comparable: 93.2% (IR-B) vs 92.8% (AV-B) (p=0.90).
• Mean aortic pressure gradients and left ventricular mass index changes were similar between the IR-B and AV-B groups over 3 years.

Conclusions:

• Early and midterm clinical outcomes were comparable between the INSPIRIS RESILIA bioprosthesis and the AVALUS bioprosthesis.
• Both bioprosthetic valves demonstrate similar safety and efficacy profiles in patients undergoing aortic valve replacement.
• These findings support the use of both IR-B and AV-B in clinical practice.